Artiva Biotherapeutics, Inc. is a cutting-edge biotechnology company dedicated to advancing next-generation cell therapies for cancer treatment through its proprietary platform, which enhances natural killer (NK) cell therapies. The company boasts a robust pipeline targeting various hematologic and solid tumors, underscoring its strong commitment to innovation in the immuno-oncology space. With a focus on scientific excellence and strategic collaborations, Artiva is well-positioned to drive transformative advancements in cancer care, aiming to significantly improve patient outcomes as its promising therapeutic candidates progress through clinical development.
Data last updated: May 12, 2026 at 11:05 PM EDT
Get e-mail RSI alerts when Artiva Biotherapeutics, Inc. Common Stock enters oversold or overbought territory. Free forever.
Add Alert